Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL7970150

N.O=C(O)c1cccnc1O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 3/20 0.64
KDM4E B2RXH2 5/20 0.63
TDP1 Q9NUW8 1/20 0.63
ALDH1A1 P00352 7/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
ALOX15 P16050 2/20 0.61
CYP3A4 P08684 1/20 0.61
MAPT P10636 1/20 0.61
TSHR P16473 1/20 0.61
BLM P54132 1/20 0.61
AGER Q15109 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.59
LMNA P02545 2/20 0.59
DHODH Q02127 2/20 0.50
ALOX12 P18054 1/20 0.50
KDM6B O15054 1/20 0.50
KDM6A O15550 1/20 0.50
TET3 O43151 1/20 0.50
KDM4A O75164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL7970154 1.00 NAPRT (0.64) NAPRTKDM4ETDP1ALDH1A1L3MBTL1
SCHEMBL107538 0.98 NAPRT (0.67) NAPRTKDM4ETDP1ALDH1A1L3MBTL1
SCHEMBL29514689 0.98 NAPRT (0.67) NAPRTKDM4ETDP1ALDH1A1L3MBTL1
SCHEMBL7904344 0.96 NAPRT (0.64) NAPRTKDM4ETDP1ALDH1A1L3MBTL1
Hydrochloric Acid SCHEMBL2164505 0.96 NAPRT (0.64) NAPRTKDM4ETDP1ALDH1A1L3MBTL1
SCHEMBL10631520 0.96 NAPRT (0.64) NAPRTKDM4ETDP1ALDH1A1L3MBTL1
Hydrochloric Acid SCHEMBL2164502 0.94 NAPRT (0.62) NAPRTKDM4ETDP1ALDH1A1L3MBTL1
Pyridine SCHEMBL28979292 0.88 NAPRT (0.56) NAPRTKDM4ETDP1ALDH1A1L3MBTL1
SCHEMBL27349912 0.84 NAPRT (0.51) NAPRTKDM4ETDP1ALDH1A1L3MBTL1
SCHEMBL7301605 0.78 KDM4E (0.47) NAPRTKDM4ETDP1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001036412-A1 PROCESS FOR THE PREPARATION OF ARYLOXY PROPANOLAMINES ELI LILLY AND COMPANY (US) 2001-05-25 WO claimed
US-12129249-B2 Method for producing optically active compound DAY ONE BIOPHARMACEUTICALS, INC. (US) 2024-10-29 US disclosed
EP-4406609-A2 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND Day One Biopharmaceuticals, Inc. (US) 2024-07-31 EP disclosed
EP-3632441-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND DAY ONE BIOPHARMACEUTICALS INC (US) 2024-07-17 EP disclosed
CN-117447464-A Method for producing optically active compound 首日生物制药公司 2024-01-26 CN disclosed
CN-111032047-B Method for producing optically active compound 多特疗法-1公司 2023-10-27 CN disclosed
US-20210347769-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND DAY ONE BIOPHARMACEUTICALS, INC. 2021-11-11 US disclosed
US-10988469-B2 Method for producing optically active compound DOT THERAPEUTICS-1, INC. (US) 2021-04-27 US disclosed
US-20200317659-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND DAY ONE BIOPHARMACEUTICALS, INC. 2020-10-08 US disclosed
EP-3632441-A2 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND Millennium Pharmaceuticals, Inc. (US) 2020-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10988469-B2 Method for producing optically active compound DHPS, QDPR, SPR NAPRT 263/4885KDM4E 913/4885TDP1 4637/4885
US-20200317659-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND DHPS, QDPR, SPR NAPRT 263/4885KDM4E 913/4885TDP1 4637/4885
US-12129249-B2 Method for producing optically active compound DHPS, QDPR, SPR NAPRT 263/4885KDM4E 913/4885TDP1 4637/4885
US-20210347769-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND DHPS, QDPR, SPR NAPRT 263/4885KDM4E 913/4885TDP1 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.